Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo

Domaine:

healthcare

Type de record:

paper

Créateur:

MarChiRonPau

Éditeur:

ope

Hôte:

Abstract Gambiense human African trypanosomiasis (gHAT) is marked for elimination of transmission (EOT) by 2030, but the disease persists in several low-income countries. We coupled transmission and health outcomes models to examine the cost-effectiveness of four gHAT elimination strategies in in five settings – spanning low- to high-risk – of the Democratic Republic of Congo. Alongside passive screening (PS) in fixed health facilities, the strategies included active screening (AS) at average or intensified coverage levels, alone or with vector control (VC) with a scale-back algorithm when no cases were reported for three consecutive years. In high or moderate-risk settings, costs of gHAT strategies are primarily driven by AS and, if used, VC. Due to the cessation of AS and VC, most investments (75-80%) will be made by 2030 and VC might be cost-saving while ensuring EOT. In low-risk settings, costs are driven by PS, and minimum-cost strategies consisting of AS and PS lead to EOT by 2030 with high probability .

Cost-effectiveness of end-game strategies against sleeping sickness across the Democratic Republic of Congo

Abstract Background

Inquiry in Ridding the Democratic Republic of the Congo of sleeping sickness, a dream at our fingertips: comparing to the Epidemiology of human African trypanosomiasis in the Democratic Republic of the Congo 2002-2003

Abstract Background I

Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study

Background Nifurtimox-eflornithine combination therapy (NECT) for the treatment of second stage ga

Improved Detection of Sleeping Sickness Cases by LED Fluorescence Microscopy: Evidence from a Prospective Multi-Centric Study in the Democratic Republic of the Congo

Melarsoprol Sensitivity Profile of <i>Trypanosoma brucei gambiense</i> Isolates from Cured and Relapsed Sleeping Sickness Patients from the Democratic Republic of the Congo

Background

Sleeping sickness caused by Trypanosoma brucei (T.b.) gamb

Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo